Literature DB >> 19463994

An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.

Mohammad Ali Karimzadeh1, Mojgan Javedani.   

Abstract

OBJECTIVE: To compare the effect of clomiphene citrate, metformin, and lifestyle modification on treatment of patients with polycystic ovary syndrome (PCOS).
DESIGN: Prospective randomized double-blind study.
SETTING: University-based infertility clinic and research center. PATIENT(S): Three hundred forty-three overweight infertile women with PCOS. INTERVENTION(S): The participating women were assigned to four groups: clomiphene (n = 90), metformin (n = 90), clomiphene + metformin (n = 88), and lifestyle modification (n = 75). The patients in each group received standardized dietary and exercise advice from a dietitian. MAIN OUTCOME MEASURE(S): The primary outcome variables were change in menstrual cycle, waist circumference measurements, endocrine parameters, and lipid profile. The main secondary outcome variable was clinical pregnancy rate. RESULT(S): The clinical pregnancy rate was 12.2% in clomiphene group, 14.4% in metformin group, 14.8% in clomiphene + metformin group, and 20% in lifestyle modification group. Lifestyle modification group achieved a significant reduction in waist circumference, total androgen, and lipid profile. CONCLUSION(S): Lifestyle modification improves the lipid profile in PCOS patients. Therefore, lifestyle modification may be used as the first line of ovulation induction in PCOS patients. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19463994     DOI: 10.1016/j.fertnstert.2009.02.078

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  28 in total

Review 1.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 2.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

3.  Polycystic ovary syndrome (PCOS): metformin.

Authors:  David J Cahill; Katherine O'Brien
Journal:  BMJ Clin Evid       Date:  2015-03-27

Review 4.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

Review 5.  Metformin use in women with polycystic ovary syndrome.

Authors:  Neil P Johnson
Journal:  Ann Transl Med       Date:  2014-06

6.  Metformin in women with PCOS, pros.

Authors:  Renato Pasquali; Pasquali Renato
Journal:  Endocrine       Date:  2014-06-10       Impact factor: 3.633

Review 7.  Contemporary approaches to the management of polycystic ovary syndrome.

Authors:  Renato Pasquali
Journal:  Ther Adv Endocrinol Metab       Date:  2018-02-07       Impact factor: 3.565

Review 8.  Insulin and hyperandrogenism in women with polycystic ovary syndrome.

Authors:  Catherine G Baptiste; Marie-Claude Battista; Andréanne Trottier; Jean-Patrice Baillargeon
Journal:  J Steroid Biochem Mol Biol       Date:  2009-12-28       Impact factor: 4.292

Review 9.  Reducing intergenerational obesity and diabetes risk.

Authors:  Katherine A Sauder; Natalie D Ritchie
Journal:  Diabetologia       Date:  2021-01-06       Impact factor: 10.122

10.  The function of metformin in endometrial receptivity (ER) of patients with polycyclic ovary syndrome (PCOS): a systematic review and meta-analysis.

Authors:  Lifang Yuan; Hongbo Wu; Weiyu Huang; Yin Bi; Aiping Qin; Yihua Yang
Journal:  Reprod Biol Endocrinol       Date:  2021-06-14       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.